Handa Pharmaceuticals

Handa's mission is to develop high-quality prescription medications, including proprietary therapeutics that address significant unmet patient needs, as well as to ensure access to high-barrier-to-entry generic drugs. Handa is dedicated to providing a positive, team-oriented environment where colleagues may learn, grow and develop themselves.

Handa is focused on developing high-quality prescription medications in two complementary areas: proprietary therapeutics that address significant unmet patient needs, and high-barrier-to-entry generic drugs.

We specialize in prescription pharmaceutical products that are difficult to formulate and have the capabilities to manage all aspects of the product development process through the submission of its Abbreviated New Drug Applications (ANDA) and 505(b)(2) New Drug Applications (NDA) to the United States Food and Drug Administration (FDA).

ONCORETM is Handa's proprietary drug delivery technology that was developed to create a new, clinically differentiated class of Tyrosine Kinase Inhibitor (TKI) class of oncology drugs. The proprietary ONCORETM technology offers a novel solubility profile and allows enhanced bioavailability (molecule specific).

Handa's expertise includes patent analysis, analytical development, oral drug delivery technologies, quality-by-design principles, quality assurance, clinical trial monitoring, patent litigation, process development, commercial scale-up, supply chain management and regulatory affairs. All Handa R&D team members have backgrounds in medicine, pharmaceuticals or chemistry MSc or Ph.

Handa has a solid history of successful partnering using both co-development and out-licensing business models. Our focus is to work collaboratively with our partners to build long-term value together. Please contact us at info@handapharma.com if you would like to explore a potential partnership with Handa.